Trial for People With Established Type 2 Diabetes During Ramadan

NCT02292290 · Completed

Last updated 2026-05-28

This trial is testing a new approach to managing type 2 diabetes in adults who already have the condition during the month of Ramadan.

Status Completed The study has finished.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 99 people

Who can join Ages 18–75 · all sexes

Timeline Started 2011-04 · est. completion 2012-12

Where 2 sites · United Kingdom

What this study is testing ClinicalTrials.gov NCT02292290 ↗

Description as written by the study sponsor.

Dual therapy with metformin and Liraglutide is more effective at helping people with established Type 2 Diabetes Mellitus (T2DM) observing Ramadan achieve a triple composite endpoint of weight reduction and/or maintenance and improved HaemaglobinA1c (HbA1c) and no severe hypoglycaemic events.

Treatments tested

Liraglutide also known as Victoza Drug

4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
Liraglutide also known as Victoza Drug

4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
Sulfonylurea or Pioglitazone Drug

Addition to Metformin
Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide Drug

As per clinical guidelines for prescription

Main thing measured	Composite
Sponsor	University of Leicester
Conditions studied	Type 2 Diabetes
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02292290 ↗